The disorder Endometrial Hyperplasia is known to be the excessive thickening of the endometrium surface area. This disorder is primarily the effect of the hormonal imbalance that occurs in the uterine cavity. This disorder is one of the main reasons occurs why signs and symptoms such as excessive menstruation, bleeding in between menstruation and prolonged menstruation occurs. This is condition is also known as a predisposing factor for cancer progression. Assessment should be done as soon as the signs and symptoms that are indicated above appear. If proven positive for this condition, then invasive tests should be done in order to validate the condition. This serves as the basis for the appropriate administration of treatment.
The health care provider first assesses the intra-uterine status of the patient. The usual method for this is dialatation and curettage which involves the use of speculum for viewing the endometrium. The health care provider assesses obtains the sample and sends it to the laboratory for analysis. In this situation, the sample is being analyzed for the presence of atypical cells or abnormal cells that are cancerous or might lead to cancer. Normally if the patient becomes positive for hyperplasia, the health care provider prescribes progestin therapy to the patient. This therapy utilizes the effect of the progesterone hormone.
The condition of Endometrial Hyperplasia is caused by the decrease of progesterone in the uterine cavity. The growth stimulating hormone estrogen induces the cellular proliferation in the endometrium causing it to be thick. The mechanism of thickening is the actual preparation of the uterus for possible conception. If this does not occur, the endometrium sheds off in the form of menstruation. This mechanism is normal is progesterone amount is enough to regulate the cellular growth. If progesterone becomes absent, the cells proliferates exponentially and uncontrolled. This condition causes the abnormal thickening of the endometrium.
Usually the physician prescribes women who have been diagnosed with benign progression of hyperplasia, those belonging to simple to complex hyperplasia without atypia category, to undergo another D and C after 3-4 months. Women who have been diagnosed of having this Endometrial Hyperplasia and are continuously developing even after the three to four months period have to undergo strict monitoring and treatment of progesterone.
The health care provider prescribes the use of progesterone containing contraceptives such as the intra uterine device in order to suppress the action of estrogen. If in case the hyperplasia occurring does not respond to the IUD, oral progestin is administered to the patient. This first starts with a low dose oral progestin. The result of this therapy is assessed on or before 3 months and if results are still unsatisfying, the physician prescribes a higher dose.
The patient undergoes in another three months therapy using a higher progesterone dose. Usually simple to complex hyperplasia without atypia fades upon the use of the low dose progesterone. The higher dose of progesterone may cause untoward actions such as mood alteration and increased irritability. In some cases, the higher dose of progestin therapy enables even the removal of hyperplasia with atypical manifestations. If all of these treatments fail, the usual method done is hysterectomy or the removal of the whole uterus.
